Norbert Pauk

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 96 citations · Full text

Fibrosis, Extracellular Matrix Turnover, Inflammatory Lung Disease +7

Dietary habits and lung cancer risk among non-smoking women

A Kubík, P Zatloukal, Ladislav Tomášek et al. · European Journal of Cancer Prevention · 2004 · 66 citations

Lung cancer risk among nonsmoking women in relation to diet and physical activity.

A Kubík, Pavel Zatloukal, Ladislav Tomášek et al. · PubMed · 2004 · 37 citations

Nutrition, Physical Activity, Dietary Exposure +18

The relevance of monitoring of antibodies against the Polycyclic aromatic hydrocarbon (PAH) and PAH-DNA adducts in serum in relation to lung cancer and chronic obstructive pulmonary disease (COPD)

Norbert Pauk, Šárka Klimešová, Jenna Kara et al. · Neoplasma · 2012 · 35 citations · Full text